• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer.

作者信息

Condon Benjamin, Liskaser Grace, Thangasamy Isaac A, Murphy Declan G

机构信息

Division of Cancer Surgery, Peter MacCallum Cancer Centre.

Faculty of Medicine, University of Melbourne, Melbourne, Victoria.

出版信息

Curr Opin Urol. 2020 Jul;30(4):620-622. doi: 10.1097/MOU.0000000000000694.

DOI:10.1097/MOU.0000000000000694
PMID:31725005
Abstract
摘要

相似文献

1
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer.对于转移性激素敏感性前列腺癌，应首先使用化疗而非雄激素受体靶向治疗。反对意见：新型口服药物为转移性激素敏感性前列腺癌的化疗提供了一种有吸引力的替代方案。
Curr Opin Urol. 2020 Jul;30(4):620-622. doi: 10.1097/MOU.0000000000000694.
2
[The modern treatment of metastatic castration-resistant prostate cancer].[转移性去势抵抗性前列腺癌的现代治疗]
Magy Onkol. 2019 Mar 19;63(1):41-50. Epub 2019 Jan 2.
3
The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.去势抵抗时间对阿比特龙和恩杂鲁胺治疗转移性前列腺癌疗效的影响。
Clin Genitourin Cancer. 2016 Oct;14(5):381-388. doi: 10.1016/j.clgc.2016.03.021. Epub 2016 Mar 24.
4
Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.用于前列腺癌的新型及下一代雄激素受体导向疗法：超越阿比特龙和恩杂鲁胺。
Urol Oncol. 2016 Aug;34(8):348-55. doi: 10.1016/j.urolonc.2015.05.025. Epub 2015 Jul 7.
5
Current understanding of resistance to abiraterone  and enzalutamide in advanced prostate cancer.晚期前列腺癌中对阿比特龙和恩杂鲁胺耐药的当前认识。
Clin Adv Hematol Oncol. 2016 May;14(5):316-9.
6
[Hormone therapy in prostate cancer; a pharmacotherapeutic challenge].[前列腺癌的激素治疗；药物治疗挑战]
Ned Tijdschr Geneeskd. 2015;159:A9250.
7
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.治疗转移性去势抵抗性前列腺癌患者：现有疗法的全面综述
J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18.
8
Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.转移性去势抵抗性前列腺癌：累积化疗的益处
Eur Urol. 2015 Aug;68(2):236-7. doi: 10.1016/j.eururo.2014.05.030. Epub 2014 Jun 5.
9
Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.前列腺癌：雄激素受体异常与对阿比特龙或恩杂鲁胺的耐药性。
Nat Rev Urol. 2016 Dec;13(12):697-698. doi: 10.1038/nrurol.2016.212. Epub 2016 Nov 2.
10
New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.新型抗雄激素药物与多西他赛治疗转移性激素敏感前列腺癌的比较：一项网络荟萃分析的结果。
J Urol. 2020 Apr;203(4):751-759. doi: 10.1097/JU.0000000000000636. Epub 2019 Nov 5.

引用本文的文献

1
Clinical value of transperineal prostate biopsy guided by cognitive fusion of magnetic resonance and transrectal ultrasound.磁共振与经直肠超声认知融合引导下经会阴前列腺穿刺活检的临床价值
Medicine (Baltimore). 2025 Jul 11;104(28):e43049. doi: 10.1097/MD.0000000000043049.